SAN FRANCISCO–(BUSINESS WIRE)–Better Therapeutics, Inc. (NASDAQ: BTTX), a digital prescription therapy (PDT) company developing nutritional cognitive-behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, announced today that she would participate in a webinar on Unlocking the Value of Digital Prescription Therapeutics hosted by Cowen to discuss recently published promising pivotal clinical trial data for BT-001, its digital therapeutic platform for type 2 diabetes, and how BT-001 can be used in the current diabetes treatment paradigm type 2.
WHEN: Thursday, June 16, 2022 at 10:00 a.m. ET
WHAT: The Unlocking the Value of Digital Prescription Therapeutics the webinar will be moderated by Charles Rhyee, an equity research analyst at Cowen, and will provide an opportunity to review key results from the company’s pivotal clinical trial for BT-001 and discuss how BT-001 can be used in the current type 2 diabetes treatment paradigm. Released earlier this year, the pivotal clinical trial demonstrated a significant reduction in A1c levels that exceeded results seen in patients using only pharmaceutical solutions.
Mark Berman, MD, Chief Medical Officer, Better Therapeutics
Prapti Mehta, MD, Chief Behavioral Scientist, Better Therapeutics
Marc Bonaca, MD, MPH, director of vascular research at the Colorado Prevention Center, professor of medicine at the University of Colorado School of Medicine
WHERE: Events hosted by Cowen are intended for potential and existing Cowen customers only. To listen to the event live, please contact your Cowen representative.
About Better Therapeutics
Better Therapeutics is a prescription digital therapy (PDT) company developing a new form of cognitive behavioral therapy to address the root causes of cardiometabolic disease. The company has developed a proprietary platform for the development of FDA-regulated software solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in the neural pathways of the brain so that lasting behavioral changes become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while reducing healthcare costs. Better Therapeutics’ clinically validated mobile apps are intended to be prescribed by doctors and reimbursed like traditional medicines.
For more information visit: bettertx.com